Following the positive clinical data in pancreatic cancer, ERYTECH selected metastatic triple-negative breast cancer (TNBC) as the next indication to expand the potential use of eryaspase in solid tumors. TNBC is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases.
The ongoing Phase 2/3 TRYbeCA2 trial is evaluating eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone as a first-line treatment of patients with metastatic TNBC. Target enrollment for the Phase 2 part of the trial is 64 patients. The primary endpoint is objective response rate.